Lustgarten Forms Consortium for Pancreatic Cancer Biomarker Research | GenomeWeb

NEW YORK (GenomeWeb News) – The Lustgarten Foundation for Pancreatic Cancer said today it plans to launch a $1.25 million project to develop antibodies for biomarker targets for pancreatic cancer, the Foundation said today.
 
The Pancreatic Cancer Biomarker Development Project is a consortium of four research organizations including Canary Foundation, Dana-Farber Cancer Institute, University of California at San Francisco and Van Andel Research Institute.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.